ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Medmix AG's annualized net income for the quarter that ended in Dec. 2025 was $-1.3 Mil. Medmix AG's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was $527.8 Mil. Therefore, Medmix AG's annualized ROE % for the quarter that ended in Dec. 2025 was -0.24%.
The historical rank and industry rank for Medmix AG's ROE % or its related term are showing as below:
MDMXF'
s ROE % Range Over the Past 10 Years
Min: -1.64 Med: 2.64 Max: 15.37
Current: 1.49
During the past 8 years, Medmix AG's highest ROE % was 15.37%. The lowest was -1.64%. And the median was 2.64%.
MDMXF's ROE % is ranked worse than 69.88% of 3005
companies
in the Industrial Products industry
Industry Median: 5.85
vs MDMXF: 1.49
Medmix AG (OTCPK:MDMXF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Medmix AG ROE % Related Terms
Medmix AG ROE % Historical Data
* Premium members only.
The historical data trend for Medmix AG's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Industrial Machinery subindustry, Medmix AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medmix AG ROE % vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Medmix AG's ROE % distribution charts can be found below:
* The bar in red indicates where Medmix AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Medmix AG (MDMXF) has a ROE % of -0.24% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Medmix AG and its competitors. According to the industry distribution chart, Medmix AG ranks #2100 out of 3005 companies in the Industrial Products industry, placing it in the top 69.9%.
Is Medmix AG's ROE % too high?
Medmix AG's current ROE % is -0.24%. Based on the distribution chart, Medmix AG ranks #2100 out of 3005 companies in the Industrial Products industry, which is below the industry midpoint. Overall, Medmix AG has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Medmix AG's ROE % compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Medmix AG ranks #2100 out of 3005 companies for ROE %. This places Medmix AG in the lower half of its industry. The industry median ROE % is 5.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for an Industrial Products company?
The median ROE % among Industrial Products companies is 5.85, based on 3,005 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Medmix AG and its competitors. For the Industrial Products industry, the median ROE % is 5.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medmix AG's current ROE % is -0.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medmix AG stock overvalued right now?
Medmix AG (MDMXF) has a current ROE % of -0.24%. The stock's GF Value™ is $26.13, compared to a current price of $17.40 — trading 33.4% below its estimated fair value. The current ROE % is -0.24%. Medmix AG's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Medmix AG (MDMXF), the current ROE % is -0.24% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medmix AG (MDMXF) Overvalued in 2026?
Based on GuruFocus' analysis, Medmix AG stock appears to be undervalued.
The current stock price of $17.40 is trading 33.4% below its estimated GF Value™ of $26.13.
Key valuation signals for MDMXF:
ROE %: -0.24%
GF Value™: $26.13 vs. price of $17.40 (33.4% below fair value)
No single metric tells the full story. See the MDMXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medmix AG designs and produces high-precision delivery devices for the healthcare, consumer and industrial segments. Its segments are Healthcare, Consumer & Industrial, and Others. The Healthcare segment focuses on delivery devices for the drug delivery, surgery, and dental markets, including injection pens for subcutaneous drug delivery, surgical delivery devices, and mixing and delivery systems for the dental consumable industry. The Consumer & Industrial segment focuses on delivery devices used for industrial applications such as adhesives in construction, electronics, automotive, and aerospace, as well as consumer markets such as beauty and microbrush applications. The company operates in Europe, the Middle East and Africa, the Americas, and Asia-Pacific.
61GF Score
Get the complete analysis for MDMXF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDMXF has been successfully added to your 
